DOCSLIB.ORG

2018 FDA Approvals Summary BLA, NDA, & Tentative Approvals Key Drug-Device Supplements

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2018 FDA Approvals Summary BLA, NDA, & Tentative Approvals Key Drug-Device Supplements 2018 FDA Approvals Summary BLA, NDA, & Tentative Approvals Key Drug-Device Supplements PharmaCircle LLC 2019-01-14 FDA Drugs Division - 2018 BLA Approvals (351(a) Biologics) Application Approval Marketing Application Product Name Molecule/API Name Route Dosage Form Company Name Indication Number Date Status Category 125294 GRANIX TBO-FILGRASTIM INJECTION INJECTABLE RATIOPHARM 2018-07-31 RX 351(a) Neutropenia 761051 POTELIGEO MOGAMULIZUMAB-KPKC INJECTION INJECTABLE KYOWA KIRIN 2018-08-08 RX 351(a) Mycosis Fungoides 761063 EMGALITY GALCANEZUMAB-GNLM INJECTION INJECTABLE ELI LILLY 2018-09-27 RX 351(a) Migraine 761065 TROGARZO IBALIZUMAB-UIYK INJECTION INJECTABLE TAIMED 2018-03-06 RX 351(a) Infections, HIV/AIDS, Other 761067 ILUMYA TILDRAKIZUMAB-ASMN INJECTION INJECTABLE SUN GLOBAL 2018-03-20 RX 351(a) Psoriasis, Other 761068 CRYSVITA BUROSUMAB-TWZA INJECTION INJECTABLE ULTRAGENYX 2018-04-17 RX 351(a) X-Linked Hypophosphatemia 761077 AIMOVIG ERENUMAB-AOOE INJECTION INJECTABLE AMGEN 2018-05-17 RX 351(a) Migraine 761079 PALYNZIQ PEGVALIASE-PQPZ INJECTION INJECTABLE BIOMARIN 2018-05-24 RX 351(a) Phenylketonuria 761089 AJOVY FREMANEZUMAB-VFRM INJECTION INJECTABLE TEVA 2018-09-14 RX 351(a) Migraine 761090 TAKHZYRO LANADELUMAB (SHP643) INJECTION INJECTABLE DYAX 2018-08-23 RX 351(a) Angioedema, Hereditary, Other 761092 REVCOVI ELAPEGADEMASE-LVLR INJECTION INJECTABLE LEADIANT 2018-10-05 RX 351(a) SCID, Other 761094 OXERVATE CENEGERMIN-BKBJ OPHTHALMIC SOLUTION DOMPE 2018-08-22 RX 351(a) Eye Diseases, Corneal 761097 LIBTAYO CEMIPLIMAB-RWLC INTRAVENOUS INJECTABLE REGENERON 2018-09-28 RX 351(a) Cancer, SCC CALASPARGASE 761102 ASPARLAS INTRAVENOUS INJECTABLE SERVIER 2018-12-20 RX 351(a) Cancer, ALL PEGOL-MKNL MOXETUMOMAB 761104 LUMOXITI INJECTION INJECTABLE ASTRAZENECA 2018-09-13 RX 351(a) Cancer, HCL PASUDOTOX-TDFK 761107 GAMIFANT EMAPALUMAB-LZSG INJECTION INJECTABLE NOVIMMUNE 2018-11-20 RX 351(a) Blood Cell Disorders, Other 761108 ULTOMIRIS RAVULIZUMAB-CWVZ INJECTION INJECTABLE ALEXION 2018-12-21 RX 351(a) PNH 761116 ELZONRIS TAGRAXOFUSP-ERZS INJECTION SOLUTION STEMLINE 2018-12-21 RX 351(a) Cancer, BPDCN All Rights Reserved - PharmaCircle LLC (2019) FDA Drugs Division - 2018 BLA Approvals (351(k) Biologics) Application Approval Marketing Application Product Name Molecule/API Name Route Dosage Form Company Name Indication Number Date Status Category Anemia, Cancer/Chemo- 125545 RETACRIT EPOETIN ALFA-EPBX INJECTION INJECTABLE HOSPIRA 2018-05-15 RX 351(k) Induced 761039 UDENYCA PEGFILGRASTIM-CBQV INJECTION INJECTABLE COHERUS 2018-11-02 RX 351(k) Neutropenia 761075 FULPHILA PEGFILGRASTIM-JMDB INJECTION INJECTABLE MYLAN 2018-06-04 RX 351(k) Neutropenia 761080 NIVESTYM FILGRASTIM-AAFI INJECTION INJECTABLE HOSPIRA 2018-07-20 RX 351(k) Neutropenia 761071 HYRIMOZ ADALIMUMAB-ADAZ INJECTION INJECTABLE SANDOZ 2018-10-30 RX 351(k) Psoriasis, Other 761088 TRUXIMA RITUXIMAB-ABBS INJECTION INJECTABLE CELLTRION 2018-11-28 RX 351(k) Cancer, NHL, Other 761091 HERZUMA TRASTUZUMAB-PKRB INJECTION INJECTABLE CELLTRION 2018-12-14 RX 351(k) Cancer, Breast, Other All Rights Reserved - PharmaCircle LLC (2019) FDA Vaccines, Blood & Biologics Division - 2018 BLA Approvals (351(a) Biologics) Application Marketing Application Product Name Molecule/API Name Route Dosage Form Company Name Approval Date Indication Number Status Category 125586 ANDEXXA ANDEXANET ALFA INJECTION INJECTABLE PORTOLA 2018-05-03 RX 351(a) Hemostasis Infections, Diphtheria, Pertus- SANOFI 125563 VAXELIS VAXELIS INJECTION INJECTABLE 2018-12-26 RX 351(a) sis, Poliomyelitis, Haemophilus, PASTEUR Hepatitis B, Tetanus Primary humoral immunodefi- IMMUNOGLOBULIN G, HU- 125587 PANZYGA INJECTION INJECTABLE OCTAPHARMA 2018-08-02 RX 351(a) ciency, Chronic immune MAN PLASMA-DERIVED thrombocytopenic purpura BIO PRODUCTS Hypovolemia, ascites, 125644 ALBUMINEX SERUM ALBUMIN, HUMAN INJECTION INJECTABLE 2018-06-19 RX 351(a) LABORATORY hypoalbuminemia 125661 JIVI DAMOCTOCOG ALFA PEGOL INJECTION INJECTABLE BAYER 2018-08-29 RX 351(a) Hemophilia A All Rights Reserved - PharmaCircle LLC (2019) FDA Drugs Division - 2018 NDA (New Drug) Approvals, Type 1 (New Molecular Entity) (1/2) Application Marketing Application Product Name Molecule/API Name Route Dosage Form Company Name Approval Date Indication Number Status Category 206709 DIACOMIT STIRIPENTOL ORAL CAPSULE BIOCODEX 2018-08-20 RX Type 1 Myoclonic Seizure SODIUM ZIRCONIUM 207078 LOKELMA ORAL FOR SUSPENSION ASTRAZENECA 2018-05-18 RX Type 1 Hyperkalemia CYCLOSILICATE 207924 OLUMIANT BARICITINIB ORAL TABLET ELI LILLY 2018-05-31 RX Type 1 Rheumatoid Arthritis, AMIFAMPRIDINE Lambert Eaton Myasthenic 208078 FIRDAPSE ORAL TABLET CATALYST 2018-11-28 RX Type 1 PHOSPHATE Syndrome MIGALASTAT 208623 GALAFOLD ORAL CAPSULE AMICUS 2018-08-10 RX Type 1 Fabry Disease HYDROCHLORIDE 208627 TPOXX TECOVIRIMAT ORAL CAPSULE SIGA TECHNO. 2018-07-13 RX Type 1 Infections, Smallpox 208700 LUTATHERA LUTETIUM DOTATATE LU-177 INTRAVENOUS SOLUTION AAA USA 2018-01-26 RX Type 1 Cancer, Neuroendocrine LOFEXIDINE US 209229 LUCEMYRA ORAL TABLET 2018-05-16 RX Type 1 Opioid Dependence HYDROCHLORIDE WORLDMEDS FOSTAMATINIB Idiopathic Thrombocytopenic 209299 TAVALISSE ORAL TABLET RIGEL 2018-04-17 RX Type 1 DISODIUM Purpura SARECYCLINE 209521 SEYSARA ORAL TABLET ALLERGAN 2018-10-01 RX Type 1 Acne HYDROCHLORIDE SEGESTERONE ACETATE; POPULATION 209627 ANNOVERA VAGINAL RING 2018-08-10 RX Type 1 Contraception ETHINYL ESTRADIOL COUNCIL 209816 NUZYRA OMADACYCLINE TOSYLATE ORAL TABLET PARATEK 2018-10-02 RX Type 1 Infections, SSTI 209817 NUZYRA OMADACYCLINE TOSYLATE INTRAVENOUS POWDER PARATEK 2018-10-02 RX Type 1 Infections, SSTI 210166 MOTEGRITY PRUCALOPRIDE ORAL TABLET SHIRE 2018-12-14 RX Type 1 Constipation, 210238 DOPTELET AVATROMBOPAG MALEATE ORAL TABLET AKARX 2018-05-21 RX Type 1 Thrombocytopenia 210303 ZEMDRI PLAZOMICIN SULFATE INTRAVENOUS SOLUTION ACHAOGEN 2018-06-25 RX Type 1 Infections, Urinary Tract 210365 EPIDIOLEX CANNABIDIOL ORAL SOLUTION GW RESEARCH 2018-09-28 RX Type 1 Myoclonic Seizure 210450 ORILISSA ELAGOLIX SODIUM ORAL TABLET ABBVIE 2018-07-23 RX Type 1 Pain Management, FOSNETUPITANT CHLORIDE HYDROCHLORIDE; 210493 AKYNZEO INTRAVENOUS POWDER HELSINN 2018-04-19 RX Type 1 Nausea-Emesis PALONOSETRON HYDROCHLORIDE All Rights Reserved - PharmaCircle LLC (2019) FDA Drugs Division - 2018 NDA (New Drug) Approvals, Type 1 (New Molecular Entity) (2/2) Application Marketing Application Product Name Molecule/API Name Route Dosage Form Company Name Approval Date Indication Number Status Category 210598 YUPELRI REVEFENACIN INHALATION SOLUTION MYLAN 2018-11-09 RX Type 1 COPD 210656 DAURISMO GLASDEGIB ORAL TABLET PFIZER 2018-11-21 RX Type 1 Cancer, AML 210795 KRINTAFEL TAFENOQUINE SUCCINATE ORAL TABLET GSK 2018-07-20 RX Type 1 Infections, Malaria 210806 PIFELTRO DORAVIRINE ORAL TABLET MSD MERCK 2018-08-30 RX Type 1 Infections, HIV/AIDS 210854 XOFLUZA BALOXAVIR MARBOXIL ORAL TABLET GENENTECH 2018-10-24 RX Type 1 Infections, Influenza LOXO 210861 VITRAKVI LAROTRECTINIB ORAL CAPSULE 2018-11-26 RX Type 1 Cancer, Solid ONCOLOGY 210867 MOXIDECTIN MOXIDECTIN ORAL TABLET MDGH 2018-06-13 RX Type 1 Infections, Onchocerciasis 210868 LORBRENA LORLATINIB ORAL TABLET PFIZER 2018-11-02 RX Type 1 Cancer, NSCLC TABLET, DELAYED COSMO 210910 AEMCOLO RIFAMYCIN ORAL 2018-11-16 RX Type 1 Infections, ETEC RELEASE TECHNOLOGIES 210922 ONPATTRO PATISIRAN SODIUM INTRAVENOUS SOLUTION ALNYLAM 2018-08-10 RX Type 1 Amyloidosis 210923 MULPLETA LUSUTROMBOPAG ORAL TABLET SHIONOGI 2018-07-31 RX Type 1 Thrombocytopenia JANSSEN 210951 ERLEADA APALUTAMIDE ORAL TABLET 2018-02-14 RX Type 1 Cancer, CRPC BIOTECH ERAVACYCLINE Infections, Complicated 211109 XERAVA INTRAVENOUS POWDER TETRAPHASE 2018-08-27 RX Type 1 DIHYDROCHLORIDE Intra-Abdominal 211155 COPIKTRA DUVELISIB ORAL CAPSULE VERASTEM 2018-09-24 RX Type 1 Cancer, CLL Familial Amyloid 211172 TEGSEDI INOTERSEN SODIUM SUBCUTANEOUS SOLUTION AKCEA 2018-10-05 RX Type 1 Polyneuropathy 211192 TIBSOVO IVOSIDENIB ORAL TABLET AGIOS 2018-07-20 RX Type 1 Cancer, AML 211349 XOSPATA GILTERITINIB ORAL TABLET ASTELLAS 2018-11-28 RX Type 1 Cancer, AML 211651 TALZENNA TALAZOPARIB TOSYLATE ORAL CAPSULE PFIZER 2018-10-16 RX Type 1 Cancer, Breast Metastatic LOXO 211710 VITRAKVI LAROTRECTINIB ORAL SOLUTION 2018-11-26 RX Type 1 Cancer, Solid ONCOLOGY SYMDEKO IVACAFTOR; IVACAFTOR, 210491 ORAL TABLET, TABLET VERTEX 2018-02-12 RX Type 1 Cystic Fibrosis (COPACKAGED) TEZACAFTOR All Rights Reserved - PharmaCircle LLC (2019) FDA Drugs Division - 2018 NDA (New Drug) Approvals, Type 1 (New Molecular Entity / New Combination) Application Marketing Application Product Name Molecule/API Name Route Dosage Form Company Name Approval Date Indication Number Status Category BICTEGRAVIR SODIUM; GILEAD 210251 BIKTARVY EMTRICITABINE; TENOFOVIR ORAL TABLET 2018-02-07 RX Type 1, 4 Infections, HIV/AIDS, SCIENCES ALAFENAMIDE FUMARATE ARRAY 210496 BRAFTOVI ENCORAFENIB ORAL CAPSULE 2018-06-27 RX Type 1, 4 Cancer, Melanoma Metastatic BIOPHARMA ARRAY 210498 MEKTOVI BINIMETINIB ORAL TABLET 2018-06-27 RX Type 1, 4 Cancer, Melanoma Metastatic BIOPHARMA 211288 VIZIMPRO DACOMITINIB ORAL TABLET PFIZER 2018-09-27 RX Type 1, 4 Cancer, NSCLC Metastatic 210589 OMEGAVEN FISH OIL TRIGLYCERIDES INTRAVENOUS EMULSION FRESENIUS KABI 2018-07-27 RX Type 1, 4 Cholestasis All Rights Reserved - PharmaCircle LLC (2019) FDA Drugs Division - 2018 NDA (New Drug) Approvals, Type 1 (New Active Ingredient) Application Marketing Application Product Name Molecule/API Name Route Dosage Form Company Name Approval Date Indication Number Status Category ASCORBIC ACID; POLYETHYLENE
Load more

Recommended publications
  • Blood Modifier Agents Policy #: Rx.01.208
    Pharmacy Policy Bulletin Title: Blood Modifier Agents Policy #: Rx.01.208 Application of pharmacy policy is determined by benefits and contracts. Benefits may vary based on product line, group, or contract. Some medications may be subject to precertification, age, quantity, or formulary restrictions (ie limits on non-preferred drugs). Individual member benefits must be verified. This pharmacy policy document describes the status of pharmaceutical information and/or technology at the time the document was developed. Since that time, new information relating to drug efficacy, interactions, contraindications, dosage, administration routes, safety, or FDA approval may have changed. This Pharmacy Policy will be regularly updated as scientific and medical literature becomes available. This information may include new FDA-approved indications, withdrawals, or other FDA alerts. This type of information is relevant not only when considering whether this policy should be updated, but also when applying it to current requests for coverage. Members are advised to use participating pharmacies in order to receive the highest level of benefits. Intent: The intent of this policy is to communicate the medical necessity criteria for eltrombopag olamine (Promacta®), fostamatinib disodium (Tavalisse™), avatrombopag (Doptelet®), lusutrombopag (Mulpleta®) as provided under the member's prescription drug benefit. Description: Idiopathic thrombocytopenia purpura (ITP): ITP is an immune disorder in which the blood doesn't clot normally. ITP can cause excessive bruising and bleeding and can be characterized as an unusually low level of platelets, or thrombocytes, in the blood results in ITP. Thrombocytopenia in patients with hepatitis C: Thrombocytopenia can occur in patients with chronic hepatitis C virus (HCV) infection.
    [Show full text]
  • Multiple Technology Appraisal Avatrombopag and Lusutrombopag
    Multiple Technology Appraisal Avatrombopag and lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing an elective procedure [ID1520] Committee papers © National Institute for Health and Care Excellence 2019. All rights reserved. See Notice of Rights. The content in this publication is owned by multiple parties and may not be re-used without the permission of the relevant copyright owner. NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE MULTIPLE TECHNOLOGY APPRAISAL Avatrombopag and lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing an elective procedure [ID1520] Contents: 1 Pre-meeting briefing 2 Assessment Report prepared by Kleijnen Systematic Reviews 3 Consultee and commentator comments on the Assessment Report from: • Shionogi 4 Addendum to the Assessment Report from Kleijnen Systematic Reviews 5 Company submission(s) from: • Dova • Shionogi 6 Clarification questions from AG: • Questions to Shionogi • Clarification responses from Shionogi • Questions to Dova • Clarification responses from Dova 7 Professional group, patient group and NHS organisation submissions from: • British Association for the Study of the Liver (BASL) The Royal College of Physicians supported the BASL submission • British Society of Gastroenterology (BSG) 8 Expert personal statements from: • Vanessa Hebditch – patient expert, nominated by the British Liver Trust • Dr Vickie McDonald – clinical expert, nominated by British Society for Haematology • Dr Debbie Shawcross – clinical expert, nominated by Shionogi © National Institute for Health and Care Excellence 2019. All rights reserved. See Notice of Rights. The content in this publication is owned by multiple parties and may not be re-used without the permission of the relevant copyright owner. MTA: avatrombopag and lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing an elective procedure Pre-meeting briefing © NICE 2019.
    [Show full text]
  • Justification
    Justification to the Resolution of the Federal Joint Committee (G-BA) on an Amendment of the Pharmaceuticals Directive (AM ‑ RL): Annex XII – Resolutions on the Benefit Assessment of Medicinal Products with New Active Ingredients in Accordance with Section 35a SGB V Damoctocog alfa pegol From 20 June 2019 Contents 1. Legal basis ................................................................................................................ 2 2. Key points of the resolution ..................................................................................... 2 2.1 Additional benefit of the medicinal product in relation to the appropriate comparator therapy ..................................................................................................... 3 2.1.1 Approved therapeutic indication of damoctocog alfa pegol (Jivi®) in accordance with the summary of product characteristics ............................................ 3 2.1.2 Appropriate comparator therapy ................................................................... 3 2.1.3 Extent and probability of the additional benefit .............................................. 5 2.1.4 Summary of the assessment ........................................................................ 6 2.2 Number of patients or demarcation of patient groups eligible for treatment ...... 6 2.3 Requirements for a quality-assured application ................................................ 7 2.4 Treatment costs ..............................................................................................
    [Show full text]
  • Management of Flood Syndrome: What Can We Do Better? Strainiene S, Peciulyte M, Strainys T, Stundiene I, Savlan I, Liakina V, Valantinas J
    ISSN 1007-9327 (print) ISSN 2219-2840 (online) World Journal of Gastroenterology World J Gastroenterol 2021 August 28; 27(32): 5297-5459 Published by Baishideng Publishing Group Inc World Journal of W J G Gastroenterology Contents Weekly Volume 27 Number 32 August 28, 2021 OPINION REVIEW 5297 Management of Flood syndrome: What can we do better? Strainiene S, Peciulyte M, Strainys T, Stundiene I, Savlan I, Liakina V, Valantinas J REVIEW 5306 Radiomics and machine learning applications in rectal cancer: Current update and future perspectives Stanzione A, Verde F, Romeo V, Boccadifuoco F, Mainenti PP, Maurea S 5322 Could the burden of pancreatic cancer originate in childhood? Diaconescu S, Gîlcă-Blanariu GE, Poamaneagra S, Marginean O, Paduraru G, Stefanescu G MINIREVIEWS 5341 Application of artificial intelligence in preoperative imaging of hepatocellular carcinoma: Current status and future perspectives Feng B, Ma XH, Wang S, Cai W, Liu XB, Zhao XM 5351 Artificial intelligence application in diagnostic gastrointestinal endoscopy - Deus ex machina? Correia FP, Lourenço LC 5362 Faecal microbiota transplantation enhances efficacy of immune checkpoint inhibitors therapy against cancer Kang YB, Cai Y 5376 Immune checkpoint inhibitor-related hepatotoxicity: A review Remash D, Prince DS, McKenzie C, Strasser SI, Kao S, Liu K ORIGINAL ARTICLE Basic Study 5392 Therapeutic effect of Cistanche deserticola on defecation in senile constipation rat model through stem cell factor/C-kit signaling pathway Zhang X, Zheng FJ, Zhang Z 5404 Recombinant angiopoietin-like
    [Show full text]
  • Nutrition and Blood
    Greater Manchester Joint Formulary Chapter 9: Nutrition and Blood For cost information please go to the most recent cost comparison charts Contents 9.1. Anaemias and some other blood disorders 9.2 Fluids and electrolytes 9.3 Not listed 9.4. Oral nutrition 9.5 Minerals 9.6 Vitamins Key Red drug see GMMMG RAG list Click on the symbols to access this list Amber drug see GMMMG RAG list Click on the symbols to access this list Green drug see GMMMG RAG list Click on the symbols to access this list If a medicine is unlicensed this should be highlighted in the template as follows Drug name Not Recommended OTC Over the Counter In line with NHS England guidance, GM do not routinely support prescribing for conditions which are self-limiting or amenable to self-care. For further details see GM commissioning statement. Order of Drug Choice Where there is no preferred 1st line agent provided, the drug choice appears in alphabetical order. Return to contents Chapter 9 – page 1 of 16 V5.2 Greater Manchester Joint Formulary BNF chapter 9 Nutrition and Blood Section 9.1. Anaemias and some other blood disorders Subsection 9.1.1 Iron-deficiency anaemias Subsection 9.1.1.1 Oral iron First choice Ferrous fumarate 322 mg tabs (100 mg iron) Ferrous fumarate 305 mg caps (100 mg iron) Alternatives Ferrous fumarate 210 mg tabs (68 mg iron) Ferrous sulphate 200 mg tabs (65 mg iron) Ferrous fumarate 140 mg sugar free syrup (45 mg of iron/5 mL) Sodium feredetate 190 mg sugar free elixir (27.5 mg of iron/5 mL) Grey drugs Ferric maltol capsules Items which Criterion 2 (see RAG list) are listed as For treatment of iron deficiency anaemia in patients with Grey are intolerance to, or treatment failure with, two oral iron deemed not supplements.
    [Show full text]
  • Doptelet® (Avatrombopag) (Oral) Document Number: IC-0369 Last Review Date: 02/04/2020 Date of Origin: 07/03/2018 Dates Reviewed: 07/2018, 02/2019, 08/2019, 02/2020
    Doptelet® (avatrombopag) (Oral) Document Number: IC-0369 Last Review Date: 02/04/2020 Date of Origin: 07/03/2018 Dates Reviewed: 07/2018, 02/2019, 08/2019, 02/2020 I. Length of Authorization Thrombocytopenia due to CLD Coverage is provided for one 5-day course of therapy and may not be renewed. Chronic ITP Coverage is provided for three months and may be renewed. II. Dosing Limits A. Quantity Limit (max daily dose) [NDC unit]: 20 mg tablets: 3 tablets per day B. Max Units (per dose and over time) [HCPCS Unit]: Thrombocytopenia 60 mg daily Chronic ITP 40 mg daily III. Initial Approval Criteria1 Coverage is provided in the following conditions: Universal Criteria Patient age 18 years or older; AND Patient is not on any other thrombopoietin receptor agonist or mimetic (e.g., romiplostim, eltrombopag, lusutrombopag, etc.) or fostamtinib; AND Avatrombopag is not being used to attempt to normalize platelet count; AND Laboratory values are current (i.e., drawn within the previous 28 days); AND Thrombocytopenia due to Chronic Liver Disease (CLD) † Proprietary & Confidential © 2020 Magellan Health Inc. Patient is scheduled to undergo a procedure with a risk of bleeding which would necessitate a platelet transfusion; AND Patient will not be undergoing any of the following procedures: Neurosurgical intervention; Thoracotomy; Laparotomy; Organ resection; AND The patient is at increased risk for bleeding as indicated by platelet count of less than < 50 x 109/L Chronic Immune Thrombocytopenia (ITP) † Patient has had chronic ITP for
    [Show full text]
  • (ITP)—Focus on Thrombopoietin Receptor Agonists
    21 Review Article Page 1 of 21 The treatment of immune thrombocytopenia (ITP)—focus on thrombopoietin receptor agonists David J. Kuter Hematology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA Correspondence to: Professor David J. Kuter, MD, DPhil. Hematology Division, Massachusetts General Hospital, Ste. 118, Room 110, Zero Emerson Place, Boston, MA 02114, USA. Email: [email protected]. Abstract: Immune thrombocytopenia (ITP) is an autoimmune disease characterized by increased platelet destruction along with reduced platelet production. All treatments attempt either to reduce the rate of platelet production or increase the rate of platelet production. There is no known cure but most patients attain a hemostatic platelet count. New treatment guidelines have supported a shift from corticosteroids and splenectomy to newer medical treatments that mitigate the thrombocytopenia and avoid splenectomy. The thrombopoietin receptor agonists (TPO-RA), romiplostim, eltrombopag, and avatrombopag, have markedly altered the treatment of ITP. Response rates of 80–90% are routinely obtained and responses are usually maintained with continued therapy. Data shows that TPO-RA are just as effective in early ITP as in chronic ITP and current guidelines encourage their use as early as 3 months into the disease course, sometimes even earlier. TPO-RA do not need to be continued forever; about a third of patients in the first year and about another third after two years have a remission. Whether TPO-RA affect the ITP pathophysiology and directly cause remission remains unclear. This review provides a personal overview of the diagnosis and treatment of ITP with a focus on the mechanism of action of TPO-RA, their place in the treatment algorithm, unique aspects of their clinical use, adverse effects, and options should they fail.
    [Show full text]
  • 2016 Medicines in Development for Rare Diseases a LIST of ORPHAN DRUGS in the PIPELINE
    2016 Medicines in Development for Rare Diseases A LIST OF ORPHAN DRUGS IN THE PIPELINE Autoimmune Diseases Product Name Sponsor Official FDA Designation* Development Status Actemra® Genentech treatment of systemic sclerosis Phase III tocilizumab South San Francisco, CA www.gene.com Adempas® Bayer HealthCare Pharmaceuticals treatment of systemic sclerosis Phase II riociguat Whippany, NJ www.pharma.bayer.com ARA 290 Araim Pharmaceuticals treatment of neuropathic pain in patients Phase II Tarrytown, NY with sarcoidosis www.ariampharma.com ARG201 arGentis Pharmaceuticals treatment of diffuse systemic sclerosis Phase II (type 1 native bovine skin Collierville, TN www.argentisrx.com collagen) BYM338 Novartis Pharmaceuticals treatment of inclusion body myositis Phase III (bimagrumab) East Hanover, NJ www.novartis.com CCX168 ChemoCentryx treatment of anti-neutrophil cytoplasmic Phase II (5a receptor antagonist) Mountain View, CA auto-antibodies associated vasculitides www.chemocentryx.com (granulomatosis with polyangitis or Wegener's granulomatosis), microscopic polyangitis, and Churg-Strauss syndrome * This designation is issued by the FDA's Office of Orphan Products Development while the drug is still in development. The designation makes the sponsor of the drug eligible for entitlements under the Orphan Drug Act of 1983. The entitlements include seven years of marketing exclusivity following FDA approval of the drug for the designated use. Medicines in Development: Rare Diseases | 2016 1 Autoimmune Diseases Product Name Sponsor Official FDA
    [Show full text]
  • Avatrombopag and Lusutrombopag For
    Journals Library Health Technology Assessment Volume 24 • Issue 51 • October 2020 ISSN 1366-5278 Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis Nigel Armstrong, Nasuh Büyükkaramikli, Hannah Penton, Rob Riemsma, Pim Wetzelaer, Vanesa Huertas Carrera, Stephanie Swift, Thea Drachen, Heike Raatz, Steve Ryder, Dhwani Shah, Titas Buksnys, Gill Worthy, Steven Duffy, Maiwenn Al and Jos Kleijnen DOI 10.3310/hta24510 Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis Nigel Armstrong ,1* Nasuh Büyükkaramikli ,2 Hannah Penton ,2 Rob Riemsma ,1 Pim Wetzelaer ,2 Vanesa Huertas Carrera ,1 Stephanie Swift ,1 Thea Drachen ,1 Heike Raatz ,1 Steve Ryder ,1 Dhwani Shah ,1 Titas Buksnys ,1 Gill Worthy ,1 Steven Duffy ,1 Maiwenn Al 2 and Jos Kleijnen 1 1Kleijnen Systematic Reviews, York, UK 2Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, the Netherlands *Corresponding author Declared competing interests of authors: Rob Riemsma is a member of the National Institute for Health Research Health Technology Assessment and Efficacy and Mechanism Evaluation Editorial Board. Published October 2020 DOI: 10.3310/hta24510 This report should be referenced as follows: Armstrong N, Büyükkaramikli N, Penton H, Riemsma R, Wetzelaer P, Huertas Carrera V, et al. Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis. Health Technol Assess 2020;24(51). Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta Medica/EMBASE, Science Citation Index Expanded (SciSearch®) and Current Contents®/ Clinical Medicine.
    [Show full text]
  • Study Protocol Is Provided on the Following Pages
    Clinical Study Report E5501-G000-311 16.1.1 Protocol and Protocol Amendments The final study protocol is provided on the following pages. Eisai Confidential Page 1 of 101 Clinical Study Protocol E5501-G000-311 (Protocol Amendment 04) Revisions to V6.0: 31 May 2016 (Amendment 03) Date: V7.0: 02 Dec 2016 (Amendment 04) Change Rationale Affected Protocol Sections Sample size reduced from After consultation with the FDA, it Synopsis – approximately 300 subjects to was decided that the current study Number of Subjects approximately 200 subjects has reached adequate enrollment Sample Size to demonstrate the safety and Rationale benefit of avatrombopag in Section 9.3 reducing the need for platelet Section 9.4.3 transfusion in subjects with Section 9.7.2 thrombocytopenia and liver disease undergoing an elective procedure. The secondary endpoint, Given the rare occurrence of Synopsis – proportion of subjects with a bleeding events (less than Secondary World Health Organization expected), this endpoint is better Objectives (WHO) bleeding score ≥2 suited as an exploratory endpoint. Exploratory after randomization and up to Objectives 7 days following an elective Secondary Endpoints procedure, will be an Exploratory exploratory endpoint Endpoints Secondary Efficacy Variable Analyses Exploratory Efficacy Variables Section 8.2 Section 8.3 Section 9.7.1.1 Section 9.7.1.6 FINAL (v7.0): 02 Dec 2016 Page i of viii CONFIDENTIAL Eisai Confidential Page 2 of 101 Clinical Study Protocol E5501-G000-311 (Protocol Amendment 04) Revisions to V5.0: 22 June
    [Show full text]
  • Nplate® (Romiplostim)
    Nplate® (romiplostim) (Subcutaneous) Document Number: IC-0089 Last Review Date: 02/02/2021 Date of Origin: 01/01/2012 Dates Reviewed: 12/2011, 02/2013, 02/2014, 12/2014, 10/2015, 09/2016, 12/2016, 03/2017, 06/2017, 12/2017, 03/2018, 06/2018, 10/2018, 01/2019, 12/2019, 02/2020, 02/2021 I. Length of Authorization Coverage will be provided for 3 months and may be renewed, unless otherwise specified. • Coverage for use to treat Hematopoietic Syndrome of Acute Radiation Syndrome (HS­ARS) cannot be renewed. II. Dosing Limits A. Quantity Limit (max daily dose) [NDC Unit]: − Nplate 125 mcg SDV for injection: 4 vials per 28 days − Nplate 250 mcg SDV for injection: 20 vials per 28 days − Nplate 500 mcg SDV for injection: 12 vials per 28 days B. Max Units (per dose and over time) [HCPCS Unit]: • ITP: 125 billable units weekly • MDS: 100 billable units weekly • HS­ARS: 125 billable units x 1 dose III. Initial Approval Criteria 1,3,13,14 Coverage is provided in the following conditions: Universal Criteria 1 • Patient is not on any other thrombopoietin receptor agonist or mimetic (e.g., lusutrombopag, eltrombopag, avatrombopag, etc.) or fostamatinib; AND • Must not be used in an attempt to normalize platelet counts; AND • Laboratory value for platelet count is current (i.e., drawn within the previous 28 days); AND Immune (idiopathic) thrombocytopenia (ITP) † Ф 1,4­12 Proprietary & Confidential © 2021 Magellan Health, Inc. • The patient is at increased risk for bleeding as indicated by platelet count less than 30 × 109/L (30,000/mm³); AND o Patient has acute ITP; AND .
    [Show full text]
  • Active Data Protection Period Register of Innovative Drugs
    Register Of Innovative Drugs Products for Human Use - Active Data Protection Period Notice of Drug(s) Containing Pediatric Submission Compliance 6 Year "No Data Protection Medicinal Ingredient(s)* Innovative Drug Manufacturer the Medicinal Extension Number Date File" Date Ends Ingredient / Variations Yes / No yyyy-mm-dd abemaciclib 215268 Verzenio Eli Lilly Canada Inc. N/A 2019-04-08 2025-04-08 N/A 2027-04-08 acalabrutinib 214504 Calquence AstraZeneca Canada Inc. N/A 2019-08-23 2025-08-23 N/A 2027-08-23 aclidinium bromide 157598 Tudorza Genuair AstraZeneca Canada Inc. Duaklir Genuair 2013-07-29 2019-07-29 N/A 2021-07-29 afatinib dimaleate 158730 Giotrif Boehringer Ingelheim (Canada) Ltd. N/A 2013-11-01 2019-11-01 N/A 2021-11-01 aflibercept 149321 Eylea Bayer Inc. N/A 2013-11-08 2019-11-08 N/A 2021-11-08 albiglutide 165145 Eperzan GlaxoSmithKline Inc. N/A 2015-07-15 2021-07-15 N/A 2023-07-15 alectinib hydrochloride 189442 Alecensaro Hoffmann-La Roche Limited N/A 2016-09-29 2022-09-29 N/A 2024-09-29 alirocumab 183116 Praluent Sanofi-aventis Canada Inc. N/A 2016-04-11 2022-04-11 N/A 2024-04-11 alogliptin benzoate 158335 Nesina Takeda Canada Inc. Kazano 2013-11-27 2019-11-27 N/A 2021-11-27 Oseni anthrax antigen filtrate 212387 Biothrax Emergent Biodefense Operations N/A 2018-12-13 2024-12-13 N/A 2026-12-13 Lansing LLC anthrax immune globulin (human) 200446 Anthrasil Emergent BioSolutions Canada Inc. N/A 2017-11-06 2023-11-06 Yes 2026-05-06 antihemophilic factor (recombinant 163447 Eloctate Bioverativ Canada Inc.
    [Show full text]